Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

Several other brokerages have also recently commented on TSHA. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a report on Thursday, December 4th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, March 3rd. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $4.56 on Thursday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.82 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $6.02. The stock has a fifty day simple moving average of $4.65 and a 200 day simple moving average of $4.53.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares in the company, valued at $4,740,327.69. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer owned 1,467,635 shares in the company, valued at $6,971,266.25. This represents a 5.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 598,623 shares of company stock valued at $2,822,188. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of TSHA. Marex Group plc purchased a new position in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $31,000. ST Germain D J Co. Inc. boosted its stake in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $40,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies News Summary

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results beat consensus — adjusted EPS of ($0.08) vs. ($0.11) expected and revenue of $5.49M versus $1.89M consensus, a clear top-line and EPS surprise that likely supported the stock. Press Release
• Positive Sentiment: Clinical progress: Taysha reported dosing multiple Rett syndrome patients in the REVEAL pivotal trial of TSHA‑102 and said enrollment/dosing is advancing across sites, on track to complete dosing in Q2 2026 — a material development for value inflection in their lead program. Corporate Update
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $12 price target (~160% above current levels), which can attract momentum buyers and institutional interest. Benzinga
• Neutral Sentiment: Full earnings call transcripts and coverage are available (Seeking Alpha, Yahoo), providing more color for investors who want management’s commentary on cash runway, program timelines and next catalysts. Seeking Alpha Transcript Yahoo Finance Transcript
• Neutral Sentiment: Market context: shares are trading higher with above-average volume; technicals show the stock near its 50‑ and 200‑day moving averages, so short‑term momentum and volume dynamics may matter to traders. MarketBeat TSHA
• Negative Sentiment: Profitability concerns remain material — Taysha reported a negative return on equity (~67%) and an extremely negative net margin (~1,145%), underscoring ongoing losses and potential dilution/burn risk until late‑stage readouts or partnerships. This is a continuing downside risk for investors. Financial Results

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.